Michel Tod

List of Publications by Year
in descending order

42 papers	800 citations	516710 16 h-index	526287 27 g-index
42 all docs	42 docs citations	42 times ranked	1021 citing authors

#	Article	IF	Citations
1	Drug interactions between emergency contraceptive drugs and cytochrome inducers: literature review and quantitative prediction. Fundamental and Clinical Pharmacology, 2021, 35, 208-216.	1.9	2
2	Does DDI-Predictor Help Pharmacists to Detect Drug-Drug Interactions and Resolve Medication Issues More Effectively?. Metabolites, 2021, 11, 173.	2.9	8
3	Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile. Antimicrobial Agents and Chemotherapy, 2021, 65, e0104321.	3.2	13
4	Quantitative Prediction of Interactions Mediated by Transporters and Cytochromes: Application to Organic Anion Transporting Polypeptides, Breast Cancer Resistance Protein and Cytochrome 2C8. Clinical Pharmacokinetics, 2020, 59, 757-770.	3.5	5
5	Potential drugâ€“drug interactions associated with drugs currently proposed for COVIDâ€19 treatment in patients receiving other treatments. Fundamental and Clinical Pharmacology, 2020, 34, 530-547.	1.9	33
6	A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4. Clinical Pharmacokinetics, 2019, 58, 503-523.	3.5	10
7	In Silico Evaluation of Pharmacokinetic Optimization for Antimitogram-Based Clinical Trials. Cancer Research, 2018, 78, 1873-1882.	0.9	0
8	Identification of Cytochrome P450-Mediated Drugâ€“Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model. Clinical Pharmacokinetics, 2018, 57, 1581-1591.	3.5	8
9	Semi-Mechanistic Model for Predicting the Dosing Rate in Children and Neonates for Drugs Mainly Eliminated by Cytochrome Metabolism. Clinical Pharmacokinetics, 2018, 57, 831-841.	3.5	4
10	Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients. Cancer Chemotherapy and Pharmacology, 2018, 82, 319-327.	2.3	16
11	Pharmacokinetic interactions in mice between irinotecan and MBLâ€‰â€‰141, an ABCG2 inhibitor. Biopharmaceutics and Drug Disposition, 2017, 38, 351-362.	1.9	2
12	Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is it Worth It?. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 226-226.	2.5	2
13	Respiratory depression related to multiple drugâ€“drug interactions precipitated by a fluconazole loading dose in a patient treated with oxycodone. European Journal of Clinical Pharmacology, 2017, 73, 787-788.	1.9	5
14	A Model for Predicting the Interindividual Variability of Drug-Drug Interactions. AAPS Journal, 2017, 19, 497-509.	4.4	7
15	Comparison of the static in vivo approach to a physiologically based pharmacokinetic approach for metabolic drugâ€“drug interactions prediction. International Journal of Pharmacokinetics, 2016, 1, 25-34.	0.5	10
16	Feasibility and Utility of the Individualized Hydrocodone Therapy Based on Phenotype, Pharmacogenetics, and Pharmacokinetic Dosing. Clinical Journal of Pain, 2016, 32, 1106-1107.	1.9	1
17	Response: Is It Truly the Answer? Personalized Oxycodone Dosing Based on Pharmacogenetic Testing and Corresponding Pharmacokinetics. Pain Medicine, 2016, 17, pnv092.	1.9	1
18	Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers. Clinical Pharmacokinetics, 2016, 55, 977-990.	3.5	23

#	Article	IF	Citations
19	Quantitative Methods for Prediction of the Effect of Cytochrome P450 Gene Polymorphisms on Substrate Drug Exposure. Clinical Pharmacokinetics, 2015, 54, 319-320.	3.5	0
20	A Prediction Model of Drug Exposure in Cirrhotic Patients According to Childâ€“Pugh Classification. Clinical Pharmacokinetics, 2015, 54, 1245-1258.	3.5	14
21	Adherence to oral anticancer chemotherapy: What influences patientsâ€™ over or non-adherence? Analysis of the OCTO study through quantitativeâ€“qualitative methods. BMC Research Notes, 2015, 8, 291.	1.4	20
22	Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA). Cancer Chemotherapy and Pharmacology, 2015, 76, 939-948.	2.3	7
23	Determination of the Most Influential Sources of Variability in Tacrolimus Trough Blood Concentrations in Adult Liver Transplant Recipients: A Bottom-Up Approach. AAPS Journal, 2014, 16, 379-391.	4.4	37
24	Fractionation of daily dose increases the predicted risk of severe sorafenib-induced handâ€“foot syndrome (HFS). Cancer Chemotherapy and Pharmacology, 2014, 73, 287-297.	2.3	12
25	Reliability and Extension of Quantitative Prediction of CYP3A4-Mediated Drug Interactions Based on Clinical Data. AAPS Journal, 2014, 16, 1309-1320.	4.4	31
26	Quantitative Prediction of the Impact of Drug Interactions and Genetic Polymorphisms on Cytochrome P450 2C9 Substrate Exposure. Clinical Pharmacokinetics, 2013, 52, 199-209.	3.5	31
27	Impact of Genetic Polymorphism on Drug-Drug Interactions Mediated by Cytochromes: A General Approach. AAPS Journal, 2013, 15, 1242-1252.	4.4	42
28	Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice. Journal of Theoretical Biology, 2013, 320, 86-99.	1.7	21
29	In Vivo Quantitative Prediction of the Effect of Gene Polymorphisms and Drug Interactions on Drug Exposure for CYP2C19 Substrates. AAPS Journal, 2013, 15, 415-426.	4.4	39
30	Pharmacodynamic Models for Discrete Data. Clinical Pharmacokinetics, 2012, 51, 767-786.	3.5	6
31	Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation. Cancer Chemotherapy and Pharmacology, 2012, 69, 447-455.	2.3	10
32	Quantitative Prediction of Cytochrome P450 (CYP) 2D6-Mediated Drug Interactions. Clinical Pharmacokinetics, 2011, 50, 519-530.	3.5	43
33	Genotype-Based Quantitative Prediction of Drug Exposure for Drugs Metabolized by CYP2D6. Clinical Pharmacology and Therapeutics, 2011, 90, 582-587.	4.7	22
34	Extreme bradycardia due to multiple drugâ€“drug interactions in a patient with HIV postâ€exposure prophylaxis containing lopinavirâ€“ritonavir. British Journal of Clinical Pharmacology, 2011, 71, 621-623.	2.4	23
35	Empirical Bayes estimation of random effects of a mixed-effects proportional odds Markov model for ordinal data. Computer Methods and Programs in Biomedicine, 2011, 104, 505-513.	4.7	2
36	Links Between Cyclosporin Exposure in Tissues and Graft-Versus-Host Disease in Pediatric Bone Marrow Transplantation: Analysis by a PBPK Model. Pharmaceutical Research, 2011, 28, 531-539.	3.5	13

#	Article	IF	Citations
37	Influence of Dosing Schedule on Organ Exposure to Cyclosporin in Pediatric Hematopoietic Stem Cell Transplantation: Analysis with a PBPK Model. Pharmaceutical Research, 2010, 27, 2602-2613.	3.5	13
38	Etoposide pharmacokinetics and survival in patients with small cell lung cancer: A multicentre study. Lung Cancer, 2008, 62, 261-272.	2.0	37
39	Facilitation of Drug Evaluation in Children byÂPopulation Methods and Modellingâ€. Clinical Pharmacokinetics, 2008, 47, 231-243.	3.5	170
40	Pharmacokinetic-Pharmacodynamic Assessment of Tacrolimus in Liver-Transplant Recipients during the Early Post-Transplantation Period. Therapeutic Drug Monitoring, 2008, 30, 412-418.	2.0	33
41	Pharmacokinetic/Pharmacodynamic and Time-to-Event Models of Ribavirin-Induced Anaemia in Chronic Hepatitis C. Clinical Pharmacokinetics, 2005, 44, 417-428.	3.5	24
42	Quantitative Prediction of Adverse Event Probability Due to Pharmacokinetic Interactions. Drug Safety, 0, , .	3.2	0